AGMT
  • Die AGMT
    • Über uns
    • Vorstand
    • Team
    • Partner
    • Karriere
    • Kontakt
  • Studien
    • Hodgkin Lymphom
      • HD 21
      • AERN
      • BRESELIBET
    • Non-Hodgkin Lymphom
      • DSHNHL_NIVEAU
      • ORACLE
      • Pola-R-ICE
    • Multiples Myelom
      • MM-4
    • Pankreaskarzinom
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
  • Register
    • AIHA Registry
    • aMYELOIDr
    • ARIADNE NIS
    • CLL-Register
    • COVID-19 Register
    • LungCA Register
    • MBC Register
    • NGS Register
    • PTCL Register
  • Veranstaltungen
    • AGMT Jahresmeeting
    • Breast Cancer Talk
    • GI Cancer Summit
  • Publikationen
  • News
    • News Übersicht
    • Newsletter
    • News Archiv
  • Kontakt
  • AAA
  • Login
  • de
    Languages
    • en English
    • de Deutsch

AGMT_PTCL Registry

Austrian Registry and Biobank of Peripheral T-cell Lymphomas

Synopsis

Short title: AGMT_PTCL-Registry

Title: Austrian Registry and Biobank of Peripheral T-cell Lymphomas

Status: open

Start: April 2013

Coordinating Investigator: Univ. Prof. Dr. Richard Greil

Protocol Contact: PD Dr. Lukas Weiss

NIS Number: NIS003003

Sponsor: AGMT gemeinnützige GmbH

Link to online CRF

Design

This registry is a prospective as well as retrospective, observational, multicentre research initiative. Data will be collected from all sites in Austria willing to participate.

Within the registry biomaterial should be collected in the AGMT biobank. Given the low incidence of PTCL, only the establishment of a substantial biobank can lay the foundations for scientifically meaningful and internationally competitive translational research.

Objectives:
  • Epidemiology of this rare disease in Austria
  • Information on type of therapy
  • Response
  • Identification of potential prognostic and predictive factors
  • Biobanking

Inclusion/Exclusion Criteria

Inclusion Criteria (selected):
  • Diagnosis of peripheral T-cell lymphomas (PTCL) according to WHO classification 2008
    (Swerdlow SH et al. IARC Press; Lyon, France, 2008.)
  • Written informed consent. Exception: Deceased patients may also be included without written consent.
  • Age > 12 years. For inclusion of patients between >12 years and <18 years of age, additional written informed consent has to be obtained by the patient’s parent(s) or guardian.

Due to the non-interventional design of the registry there are no exclusion criteria.

Register
  • Register
    • AIHA Register
    • aMYELOIDr
    • ARIADNE NIS
    • CLL-Register
    • COVID-19 Register
    • LungCA Register
    • MBC Register
    • NGS Register
    • PTCL Register
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Firmensitz und Rechnungsadresse: Gentzgasse 60/21, 1180 Wien
Zweigstelle & Zustelladresse: Wolfsgartenweg 31, 5020 Salzburg
Firmenbuchnummer: FN 289548 g
UID-Nummer: ATU63467108
+43 662 640 44 12
+ 43 664 142 25 04
+43 662 640 44 14
office@agmt.at
Copyright © AGMT gemeinnützige GmbH
  • Impressum
  • Datenschutzerklärung
  • LinkedIn AGMT